Corporate Presentation June 2025 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, statements regarding, among other things, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; the potential regulatory path forward for tebipenem HBr, the potential approval of tebipenem HBr by the U.S. Food and Drug Admini ...

暴涨、熔断！ 本周，美国发动的关税战出现多个缓和信号。 先是美国总统特朗普宣布推迟对欧盟加征高额关税的决定，释放出明显的缓和信号，引发金融市场积极反应。 欧盟贸易专员周三（5月28日）也表示，欧盟与美国保持持续的对话，探讨关税政策以及在航空、半导体、钢 铁等领域的合作。美国国家经济委员会主任哈塞特表示，将在未来看到更多贸易协议，甚至可能就在本周；对 某些国家的关税可能降至10%或更低；关税的降低将适用于提供良好条件的国家。 随后，东盟领导人在东盟峰会上表示，东盟将"继续与美国进行坦诚和建设性的对话，并承诺不会对美国关税 采取任何报复措施"。 但东盟领导人也表示，特朗普的关税计划给该地区与美国的贸易带来不确定性，并强调"迫切需要突破传统市 场，实现贸易多元化"。"我们对美国最近宣布征收单边关税及其对我们经济的潜在影响深表担忧。" 据了解，东盟成员国越南、泰国、马来西亚、印度尼西亚和柬埔寨均在美国双边贸易逆差前20名单上，特朗普 在4月初曾威胁要对这些国家征收24%至49%不等的关税。这些关税目前处于暂停执行阶段，等待谈判结果， 目前实施的普遍基线税率为10%。 5月28日，美国三大股票指数集体小幅高开，随后窄幅 ...

周三晚间，美股集体高开后出现跳水走势。 截至发稿，美股三大指数均已翻绿。 中概股涨跌不一。科技龙头普遍下跌，比亚迪股份跌超4%，拼多多、小米集团跌超3%。 | 名称 | 现价 | 涨跌幅 ▲ | | --- | --- | --- | | 比亚迪股份-ADR | 102.400 | -4.59% | | 拼多多 | 99.360 | -3.52% | | 小米集团-ADR | 32.570 | -3.09% | | 腾讯控股-ADR | 63.900 | -2.11% | | 京东集团 | 31.895 | -1.98% | | 阿里巴巴 | 117.200 | -1.94% | | 美团-ADR | 33.040 | -1.58% | | 网易 | 124.115 | -0.14% | 热门个股方面，Spero Therapeutics盘初飙涨超244%，一度触发临时停牌。消息面上，此前该公司及其合作伙伴葛兰素史克宣布，他们用于治疗尿路感染 的口服药物tebipenem HBr在一项关键的3期临床试验中达到了主要目标。 美国国家经济委员会主任哈塞特表示，将在未来看到更多贸易协议，甚至可能就在本周； 对某些国 ...

GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy. Spero’s stock price was up 245.89% at last check Wednesday following the news. The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) based on a planned interim analysis of data from 1,690 patients enrolled in the study. Also Read: GSK To Buy Phase-3 Ready Liver Di ...

暴涨、熔断！ 5月28日，美国三大股票指数集体小幅高开，随后窄幅震荡，截至发稿，道指微涨0.05%，标普500指数 涨0.01%，纳指跌0.03%。 投资者关注的焦点从贸易战引发的紧张情绪转向美国最新的税改法案。此外，科技股龙头英伟达将于周 三（5月28日）盘后发布财报。公司业绩能否持续符合市场预期将决定科技股未来的行情。 盘面上，大型科技股走势平稳，科技七巨头涨跌互现，即将发布财报的英伟达目前跌0.2%。中概股方 面，业绩不达预期的拼多多在周二（5月27日）下跌13%后，周三（5月28日）开盘继续走低，截至记者 发稿，拼多多跌近3%。 但东盟领导人也表示，特朗普的关税计划给该地区与美国的贸易带来不确定性，并强调"迫切需要突破 传统市场，实现贸易多元化"。"我们对美国最近宣布征收单边关税及其对我们经济的潜在影响深表担 忧。" 据了解，东盟成员国越南、泰国、马来西亚、印度尼西亚和柬埔寨均在美国双边贸易逆差前20名单上， 特朗普在4月初曾威胁要对这些国家征收24%至49%不等的关税。这些关税目前处于暂停执行阶段，等 待谈判结果，目前实施的普遍基线税率为10%。 此前，美国和英国、中国相继达成贸易协议，令国际贸易紧 ...

暴涨、熔断！ 5月28日，美国三大股票指数集体小幅高开，随后窄幅震荡，截至发稿，道指微涨0.05%，标普500指数涨0.01%，纳指跌0.03%。 投资者关注的焦点从贸易战引发的紧张情绪转向美国最新的税改法案。此外，科技股龙头英伟达将于周三（5月28日）盘后发布财报。公司业绩能否持续符合市场 预期将决定科技股未来的行情。 盘面上，大型科技股走势平稳，科技七巨头涨跌互现，即将发布财报的英伟达目前跌0.2%。中概股方面，业绩不达预期的拼多多在周二（5月27日）下跌13%后，周 三（5月28日）开盘继续走低，截至记者发稿，拼多多跌近3%。 热门个股方面，Spero Therapeutics盘初飙涨至228%，一度触发临时停牌。 消息面上，此前该公司及其合作伙伴 葛兰素史克 宣布，他们用于治疗尿路感染的口服药 物 tebipenem HBr 在一项关键的 3 期临床试验中达到了主要目标。 | us Spero Therapeutics Inc | | | | | | --- | --- | --- | --- | --- | | SPRO | | | | | | 今开 2.060 最高 2.350 2.170 | | ...

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, met its primary endpoint and will stop early for efficacy (NCT06059846).3 The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) that completed a pre-specified inte ...

Core Viewpoint - Spero Therapeutics is focused on advancing its tebipenem HBr clinical program, which aims to provide an oral carbapenem option for complicated urinary tract infections, with an interim analysis of the ongoing Phase 3 PIVOT-PO trial expected in Q2 2025 [2][7][8]. Financial Results - For Q1 2025, Spero reported a net loss of $13.9 million, compared to a net loss of $12.7 million in Q1 2024, resulting in a diluted net loss per share of $0.25 versus $0.24 in the prior year [9][18]. - Total revenue for Q1 2025 was $5.9 million, down from $9.3 million in Q1 2024, primarily due to a decrease in grant revenue, although collaboration revenue increased [9][10]. - Research and development expenses decreased to $13.6 million in Q1 2025 from $17.3 million in Q1 2024, mainly due to lower spending on the SPR720 clinical program [15]. - General and administrative expenses rose to $6.8 million in Q1 2025 from $5.9 million in Q1 2024, attributed to higher personnel-related costs and consulting fees [15]. - As of March 31, 2025, Spero had cash and cash equivalents of $48.9 million, which, along with expected milestone payments from GSK, is projected to fund operations into Q2 2026 [15]. Pipeline Update - Tebipenem HBr is being developed for the treatment of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP), with the goal of reducing inpatient therapy duration [3][8]. - The oral development program for NTM-PD was suspended in Q4 2024 after an interim analysis indicated it did not meet its primary endpoint [8]. Corporate Update - Esther Rajavelu was appointed as President and CEO of Spero effective May 2, 2025, and has been nominated for election to the Board of Directors [5].

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero’s 2025 annual meeting of stockholders. Since Janu ...

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Shai Biran - Senior Director Investor Relations Esther Rajavelu - Interim Chief Executive Officer, Chief Financial Officer Tim Keutzer - Chief Operating Officer Conference Call Participants Gavin Clarke-Gartner - Evercore ISI Athena Chin - TD Cowen Operator Good afternoon, and welcome to the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all par ...